Figure 1 - uploaded by Raveesh Kumar Singh
Content may be subject to copyright.
(A) Cervical intraepithelial neoplasia II (HE 200X). (B) Cervical intraepithelial neoplasia III (HE 200X). (C) Large cell non-keratinising squamous cell carcinoma (HE 400X). (D) Large cell keratinising squamous cell carcinoma (HE 200X).
Source publication
Cervical cancer is the most prevalent cancer among women in India. The main cause of cervical cancer is persistent human papilloma viral (HPV) infection. HPV inactivates the pRb tumour suppressor protein; thus p16 expression, which is controlled by a negative feedback mechanism, is relatively increased. Galectin-3 is directly and indirectly connect...
Context in source publication
Context 1
... cell non-keratinising squamous cell carcinoma (LCNK SCC) type was the largest sub-category comprising 48.3% (57 cases) of all the cases. Large cell keratinising squamous cell carcinoma (LCK SCC) comprised 42.4% (50 cases), LSIL comprised 3.4% (4 cases) and HSIL comprised 5.9% (7 cases) of all the cases (Figure 1). The most common presenting complaints were vaginal bleeding (87.3%), followed by weight loss (77.1%), vaginal discharge (32.2%) and pain in the abdomen (11.9%). ...
Similar publications
Objective To evaluate the role of cervical cytology (Pap smear) in the diagnosis of cervical intraepithelial neoplasia 2 or greater (CIN2 + ), presented exclusively in the endocervical canal, the clinical-epidemiological characteristics of this lesion, the necessary length of canal to be removed to treat, and the rate of invasive lesion hidden in t...
HPV genotypes were determined in 63 vaginal squamous intraepithelial neoplasia (VaIN) and 7 vaginal squamous cell carcinomas (VaSCC). Of these, 37 cases had VaIN alone, and 26 cases had both VaIN and cervical intraepithelial neoplasia (CIN) or condyloma. HPV typing was performed in scraped cells by Genosearch-31 (GS-31) and in the archived tissues...
Citations
... In 2020, cervical cancer caused approximately 340,000 deaths, with a further 600,000 new cases recorded, and this accounts for 3.4% of all deaths and 3.3% of all cancer incidents globally [2]. Around 85%of the global burden occurs in the less-developed regions, where it accounts for almost 12% of all female cancers [3] Among Bangladeshi women, cervical cancer is the second most prevalent cancer, with approximately 8,068 new cases detected yearly and causing 5214 deaths [4]. One effective means to decrease cervical cancer incidence and death is early detection of cancer and its precancerous lesions or cervical intraepithelial neoplasia (CIN) [5]. ...
... The Rb tumor suppressor function is functionally inactivated by HPV E7 oncoproteins, which results in p16 overexpression in cervical cancers [13]. This p16 overexpression is a surrogate biomarker of HPV infection and helps evaluate HPV-associated squamous and glandular neoplasia of the lower gynecologic tract [3]. Hence, p16 immunoreactivity helps detect CIN because its expression could be affected by p16 mutations [14]. ...
... p16 expression differences in the distribution were statistically highly significant . Another study showed the expression of p16 in cervical cancer showed that p16 expression was more pronounced in HSIL (a proportion of 3þ or 4þ expression was seen in >90% of cases) as compared to LSIL (where only a proportion of 1þ or 2þ expression was seen) [3]. A statistically significant association of p16 with the histological diagnosis was noted. ...
... Cervical cancer (CC) originates from human papillomavirus infection of normal cervical epithelium, developing to cervical intraepithelial neoplasia and further into invasive squamous cell carcinoma. (Farchoukh et al. 2020;Kumar et al. 2020;Ono et al. 2020). CC is still the world's second-ranked gynecological tumor and causes high mortality in developing countries' female (Asgary et al. 2020;Siegel et al. 2020). ...
Cervical cancer (CC) is a common gynecological tumor, ranking second in the female reproductive system tumor. The work aims to study the function of miR-17-5p in the occurrence and pathogenesis of CC. We collected 36 cases of CC tissues for clinical analysis, and two CC cell lines (C33a and HCC94) were obtained for cellular analysis. As expected, the up-regulated miR-17-5p and down-regulated TIMP2 were detected in CC tissues and cell lines by RT-qPCR, in contrast with their normal counterparts. Then, overexpression of miR-17-5p significantly increased the CC cells viability and colonies formation abilities. Moreover, the Transwell analysis revealed that miR-17-5p promoted the capability of invasion and migration. Meanwhile, the expression levels of MMP2 and MMP9 was inhibited by the inhibition of miR-17-5p. The luciferase analysis demonstrated that TIMP2 was the target of miR-17-5p. In addition, cell proliferation, invasion and migration in HCC94 cells were repressed by silencing miR-17-5p, which were reversed by TIMP2 knockdown. In summary, all results indicated that miR-17-5p targeted TIMP2 to modulate CC cells’ proliferation, invasion and migration through MMPs signaling pathway; and the miR-17-5p/TIMP2/MMPs signaling pathway had the potential to become a therapeutic target of CC for clinical utilization.
Background: Cervical cancer still shows a high incidence rate in developing countries. Various factors play roles in cancer progression, including Galectin 3, which contributes to apoptosis, metastasis, immune response, molecular systems, mRNA splicing, gene expression and inflammation. This study aims to prove the association between Galectin 3 expression and FIGO stage of cervical squamous cell carcinoma (SCC) patients at Prof. Dr. I.G.N.G. Ngoerah Hospital, to strengthen the evidence of Galectin 3 roles in cervical SCC prognosis. Methods: This study is an analytic observational study with a cross-sectional design. Sample size was 42. Evaluation of H-E slides was performed to assess diagnosis and FIGO. Galectin 3 expression was assessed by immunohistochemical method. Data were analyzed by Chi-Square test and prevalence risk ratio analysis using SPSS version 20.0 for Windows. Results: The mean of patients age was 52.34±9.86 years, with the highest incidence in the sixth decade age and in the early FIGO stage (IB - IIA). About 81% of patients show positive Galectin 3 expression. The relationship between Galectin 3 expression and FIGO stage was statistically significant (p=0.016). The prevalence risk analysis showed that patients with positive Galectin 3 expression had a 1.9 times greater prevalence risk of developing an advanced stage than patients with negative expression (95% CI: 1.376 - 2.593). Conclusion: There is an association between Galectin 3 expression and FIGO stage in cervical cancer patients at Prof. Dr. I.G.N.G. Ngoerah Hospital, in which patients with positive Galectin 3 have a greater risk of developing an advanced stage. Latar Belakang : Kanker serviks uteri masih menunjukkan angka insiden tinggi di negara berkembang. Berbagai faktor berperan dalam progresi kanker, salah satunya Galectin 3, yang berkontribusi dalam proses apoptosis, metastasis, respon imun, sistem molecular, mRNA splicing, ekspresi gen dan inflamasi. Penelitian ini bertujuan untuk membuktikan hubungan ekspresi Galectin 3 dengan stadium FIGO pasien karsinoma sel skuamosa (KSS) serviks di RSUP Prof. Dr. I.G.N.G. Ngoerah, untuk memperkuat bukti peran Galectin 3 pada prognosis KSS serviks. Metode: Penelitian ini merupakan penelitian observasional analitik dengan rancangan potong lintang. Besar sampel 42. Evaluasi preparat hematoxyllin-eosin dilakukan untuk menilai diagnosis dan stadium FIGO. Ekspresi Galectin 3 dinilai dengan metode imunohistokimia. Data dianalisis dengan uji Chi-Square, yang dilanjutkan dengan uji rasio risiko prevalensi menggunakan SPSS versi 20.0 untuk Windows. Hasil: Rerata usia pasien 52,34±9,86 tahun, dengan kejadian tertinggi pada kelompok umur dekade keenam dan dengan stadium FIGO dini (IB - IIA). Sekitar 81% pasien menunjukkan ekspresi Galectin 3 positif. Hubungan antara ekspresi Galectin 3 dengan stadium FIGO ditemukan signifikan secara statistik (p=0,016). Pada analisis risiko prevalensi didapatkan pasien dengan ekspresi Galectin 3 positif memiliki risiko prevalensi 1,9 kali lebih besar menjadi stadium lanjut daripada pasien dengan ekspresi negatif (95% IK: 1,376 - 2,593). Kesimpulan: Terdapat hubungan antara ekspresi Galectin 3 dengan stadium FIGO pada pasien KSS serviks di RSUP Prof. Dr. I.G.N.G. Ngoerah, di mana pasien dengan Galectin 3 positif memiliki risiko lebih besar menjadi stadium lanjut.
Objective
The aim of this study was to evaluate the prognostic value of Butyrophilin-like protein 8 (BTNL8) expression in high-risk HPV (hrHPV) infection treated with photodynamic therapy.
Methods
A total of 93 patients with hrHPV infection were enrolled as research study subjects, along with 69 healthy women who served as controls. Serum samples were obtained from each participant, and BTNL8 levels were quantified. The patients were divided into high- and low-expression groups (n = 45 and n = 48, respectively), and both groups underwent photodynamic therapy. We recorded the following data: BTNL8 expression pre-treatment and at 3/6 months post-treatment, HPV negative conversion ratio, regression rate of low-grade squamous intraepithelial lesions (LSIL), incidence of adverse reactions, complication rate, serum inflammatory factors, persistence of HPV positivity, LSIL residue or recurrence, and incidence of high-grade cervical intraepithelial lesions (HCIL).
Results
Patients with HPV infection exhibited higher BTNL8 expression than healthy individuals. Compared to the low-expression group, the high-expression group showed increased HPV negative conversion ratios, LSIL regression rates, and levels of IL-17 and IL-23. This group also demonstrated decreased total complication rate, HPV positivity persistence, LSIL residue or recurrence, and IL-10 levels. Additionally, there was no significant difference between the two groups in terms of the number of adverse reactions and cases with LSIL residue/recurrence.
Conclusion
Serum BTNL8 expression may serve as a valuable tool for early screening and prognosis monitoring of patients with hrHPV infection.
